|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Impact of parietal cell autoantibodies and non-organ-specific autoantibodies on the treatment outcome of patients with hepatitis C virus infection: A pilot study显示文摘AIM: Various side effects have been reported in patients infected with hepatitis C virus (HCV) who were treated with interferon-alpha (IFN-α), including the appearance or exacerbation of underlying autoimmune diseases and the development of a variety of organ and non-organ specific autoantibodies (NOSA). However, very few studies in adults have been strictly designed to address: whether the prevalence and the titre of organ and NOSA in serial samples of HCV-treated patients were affected by IFN-α, and the impact of these autoantibodies on the treatment outcome of HCV patients.METHODS: We investigated whether parietal cell autoantibodies (PCA) and/or NOSA were related with treatment-outcome in 57 HCV-treated patients (19 sustainedresponders, 16 relapsers, 22 non-responders). Serum samples from patients were studied blindly at three timepoints (entry, end of treatment and end of followup). For the detection of autoantibodies we used indirect immunofluorescence, commercial and in-house ELISAs.RESULTS: Sustained biochemical response was associated with ANA-negativity at the entry or end of follow up. Sustained virological response was associated with the absence of PCA at the entry. Combined virological and biochemical sustained response (CVBSR) was associated with the absence of antinuclear antibodies (ANA) at the end of follow up and PCA-negativity at the entry. Sustained virological and CVBSR were associated with a reduction of ANA and SMA titers during therapy.CONCLUSION: Although PCA and/or NOSA seropositivity should not affect the decision to treat HCV patients, the presence of some of them such as ANA, PCA and SMA before treatment or their increase during therapy with IFN- α may predict a worse response, indicating the need for a closer monitoring during treatment of HCV patients positive for these autoantibodies. | Nikolaos K.Gatselis Sarah P.Georgiadou Nikolaos Tassopoulos Kalliopi Zachou Christos Liaskos Angelos Hatzakis Georgios N.Dalekos | 2005 | World Journal of Gastroenterology2005，11，4： | 10 |
| 2 | Predicted Effects of Treatment for HCV Infection Vary Among European Countries显示文摘 | Sylvie Deuffic–Burban Pierre Deltenre Maria Buti Tommaso Stroffolini Julie Parkes Nikolai Mühlberger Uwe Siebert Christophe Moreno Angelos Hatzakis William Rosenberg Stefan Zeuzem Philippe Mathurin | 2012 | Gastroenterology2012，，4： | 2 |
| 3 | Single-step optical lift-off process显示文摘 | HATZAKIS M CANAVELLO B J SHAW J M | 1988 | IBM Journal of Research&Development1988，45，1： | 1 |
| 4 | Association of malignancy with diseases causing interstitial pulmonary changes显示文摘 | Bouros D Hatzakis K Labrakis H | | 0，，： | 1 |
| 5 | Prognostic value of serum tumor markers in patients with lung cancer显示文摘 | HATZAKIS K D FROUDARKIS M E | 2002 | Respiration2002，69，1： | 1 |
| 6 | Prognostic value of serum tumor markers in patients with lung cancer显示文摘 | Hatzakis KD Froudarakis ME Bouros D | 2002 | Respiration2002，69，1： | 1 |
| 7 | Single-step optical lift-off process显示文摘 | HATZAKIS M CANAVELLO B J SHAW J M | | 0，，04： | 1 |
| 8 | Building the business/IT relationship through knowledge management 显示文摘 | V A MARTIN T HATZAKIS M LYCETT R MACREDIE | 2004 | Journal of Information Technology Case and Applications2004，6，2： | 1 |
| 9 | Prognostic value of serum tumor markers in patients with lung cancer显示文摘 | Hatzakis KD Froudarakis ME Bouros D | | 0，，： | 1 |
| 10 | Virologic monitoring of hepatitis B virus therapy in clinical trials and practice:recommendations for a standardized approach显示文摘 | Pawlotsky JM Dusheiko G Hatzakis A | 2008 | Gastroenterology2008，134，2： | 1 |
| 11 | Thestate of hepatitis B and C in Europe:report from the hepatitis B and C summit conference显示文摘 | Hatzakis A Wait S Bruix J | 2011 | J Viral Hepat2011，，： | 1 |
| 12 | Assoclarion of malignancy with diseases causing interstitial pulmonary changes显示文摘 | Demosthenes B Kostas Hatzakis Haris Labrakis | 2002 | Chest2002，121，4： | 1 |
| 13 | Virologic monitoring of hepatitis B virus therapy in clinical trials and practice:recommendations for a standardized approach显示文摘 | Pawlotsky JM Dusheiko G Hatzakis A | 2008 | Gastroenterology2008，134，2： | 1 |
| 14 | A modified mutagenic PCR-RFLP method for Kras codon 12 and 13 mutations detection in NSCLC patients显示文摘 | HATZAKI A RAZI E ANAGNOSTOPOULOU K | 2001 | Mol Cell Probes2001，15，： | 1 |
| 15 | HBV virological assessment 显示文摘 | Hatzakis A Magiorkinis E Haida C | 2006 | J Hepatol2006，44，1： | 1 |
| 16 | Prognostic value of serum tumor markers in patients with lung cancer显示文摘 | Hatzakis KD Froudarakis ME Bouros D | 2002 | Respiration2002，69，1： | 1 |
| 17 | HBV virological assessment显示文摘 | Hatzakis A Magiorkinis E Haida C | 2006 | J Hepatol2006，44，1： | 1 |
| 18 | The state of hepatitis B and C in Europe:report from the hepatitis B and C summit conference 显示文摘 | Hatzakis A Wait S Bruix J | 2011 | J Viral Hepat2011，18，1： | 1 |
| 19 | Acoustic reflectance of pha-ryngeal structures inchildren显示文摘 | Karson N Cook J | 2003 | Int J Pediatr Otorhinolaryngol2003，67，4： | 1 |
| 20 | Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach显示文摘 | Pawlotsky JM Dusheiko G Hatzakis A | 2008 | Gastro enterology2008，134，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员